RE:$13.50 target Expanding Reach in Missouri is Notable, Given COPD Prevalence in the State, and Adjacent Regions: As noted in our initiation last month, approximately 80% of Quipt's revenue relates to the treatment of respiratory diseases, and key products include oxygen concentrators and non-invasive ventilators (NIV), which are used to treat conditions such as asthma and chronic obstructive pulmonary disease (COPD).
The Company's expanded reach in Missouri is particularly notable as this is a region that has one of the highest levels of COPD prevalence in the US (Figure 2B). On a per-physician basis, the Company should have access to more potential patients.
Furthermore, the Company's positioning in Missouri significantly strengthens its overall interconnected healthcare network and the newly expanded footprint in the state will serve as a foundation for other adjacent states (e.g. Oklahoma, another state where COPD prevalence is high).